
Spirit Airlines said Tuesday its board will decide on competing offers from JetBlue Airways and Frontier Airlines before a shareholder meeting at the end of the month as the battle for the discount carrier heats up.
“The Board expects to bring the process to a conclusion and provide an update to stockholders” ahead of its June 30 meeting, Spirit CEO Ted Christie said in a statement.
Spirit postponed a meeting where shareholders would vote on the existing Frontier deal from June 10 until June 30 to review the bids.
Shares of JetBlue were down more than 1% and Spirit was up slightly in late-morning trading after Spirit’s statement. Frontier shares were off less than 1%.
JetBlue made a sweetened offer to buy Spirit on June 6, raising a reverse break-up fee to $350 million should regulators not approve the acquisition. Spirit has had a merger agreement with fellow ultra-low-cost airline Frontier since February and is still bound by the terms of that cash-and-stock deal, it said.
Frontier offered a $250 million reverse break-up fee. JetBlue included prepaying $1.50 a share from the break-up fee to shareholders to raise its offer from $30 a share to $31.50 in cash.
“As part of this process, Frontier and JetBlue are being given access to the same due diligence information, on the same terms,” Christie said.
JetBlue previously accused Spirit of not granting equal access to its information after Spirit repeatedly rebuffed JetBlue’s buyout offers.
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Trump Administration Steps Up Pressure On EU Digital Laws
May 18, 2025 by
CPI
Elton John Slams UK Government’s AI Copyright Plan as ‘Theft’
May 18, 2025 by
CPI
Anthropic’s Legal Team Blames AI “Hallucination” for Citation Error in Copyright Lawsuit
May 18, 2025 by
CPI
Intel Challenges €376 Million EU Antitrust Fine in Ongoing Legal Battle
May 18, 2025 by
CPI
FTC Chairman Highlights Fiscal Responsibility and Consumer Protection in House Testimony
May 18, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Healthcare Antitrust
May 14, 2025 by
CPI
Healthcare & Antitrust: What to Expect in the New Trump Administration
May 14, 2025 by
Nana Wilberforce, John W O'Toole & Sarah Pugh
Patent Gaming and Disparagement: Commission Fines Teva For Improperly Protecting Its Blockbuster Medicine
May 14, 2025 by
Blaž Višnar, Boris Andrejaš, Apostolos Baltzopoulos, Rieke Kaup, Laura Nistor & Gianluca Vassallo
Strategic Alliances in the Pharma Sector: An EU Competition Law Perspective
May 14, 2025 by
Christian Ritz & Benedikt Weiss
Monopsony Power in the Hospital Labor Market
May 14, 2025 by
Kevin E. Pflum & Christian Salas